Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs

As a continuation of our earlier work against SARS-CoV-2, seven FDA-approved drugs were designated as the best SARS-CoV-2 nsp16-nsp10 2′-o-methyltransferase (2′OMTase) inhibitors through 3009 compounds. The in silico inhibitory potential of the examined compounds against SARS-CoV-2 nsp16-nsp10 2′-o-...

Full description

Bibliographic Details
Main Authors:	Alesawy, M.S (Author), Alsfouk, B.A (Author), Eissa, I.H (Author), El-Attar, A.-A.M.M (Author), Elkaeed, E.B (Author), Metwaly, A.M (Author), Saleh, A.M (Author)
Format:	Article
Language:	English
Published:	MDPI 2022
Subjects:	FDA approved drugs MD simulations MMPBSA molecular docking molecular fingerprints SARS-CoV-2 nsp16-nsp10 2′-o-methyltransferase structural similarity
Online Access:	View Fulltext in Publisher

by Alesawy, M.S, Alsfouk, B.A, Eissa, I.H, El-Attar, A.-A.M.M, Elkaeed, E.B, Metwaly, A.M, Saleh, A.M
Published 2022

View Fulltext in Publisher

Article

Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs

Similar Items